Celldex vaccine improves long-term brain cancer survival in study

(Reuters) - New data from a midstage trial show that Celldex Therapeutics Inc's experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer.